Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

CAR-T efficacy in large B-cell lymphoma is shaped by neoantigen-driven epitope spreading and limited by HLA loss and genomic instability

Blood (2025) 146 (Supplement 1): 107.

https://doi.org/10.1182/blood-2025-107

Published: 2025

Journal Articles

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Blood (2025) 146 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2025-1027

Published: 2025

Journal Articles

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Blood (2025) 146 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2025-3920

Published: 2025

Journal Articles

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Blood (2025) 146 (13): 1575–1585.

https://doi.org/10.1182/blood.2024028107

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis

Blood (2024) 144 (25): 2637–2651.

https://doi.org/10.1182/blood.2024026212

Published: 2024

Includes: Supplemental data

Journal Articles

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Blood (2024) 144 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2024-211012

Published: 2024

Journal Articles

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Tomas Jelinek, Serafim Nenarokov, Tereza Sevcikova, Eva Radova, Ondrej Venglar, Veronika Kapustova, Lucie Broskevicova, Jan Vrana, Ludmila Muronova, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Michal Simicek, Bachisio Ziccheddu, Benjamin Diamond, Francesco Maura, Ola Landgren, David Zihala, Roman Hájek

Blood (2024) 144 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2024-206825

Published: 2024

Journal Articles

Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry

Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, Tala Shekarkhand, Timothy R. Chu, Alexandra Maria Poos, Elizabeth Brown, Antje Hoering, Benjamin Diamond, Bachisio Ziccheddu, Marc S. Raab, Niels Weinhold, Ola Landgren, Faith E Davies, Alexander M. Lesokhin, Saad Z. Usmani, Francesco Maura, Gareth Morgan

Blood (2024) 144 (Supplement 1): 766.

https://doi.org/10.1182/blood-2024-203675

Published: 2024

Journal Articles

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, J Erin Wiedmeier-Nutor, Vikas A. Gupta, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rodrigo Fonseca, Michael Durante, Shannon M Matulis, Tomas Jelinek, Ola Landgren, Constantine S Mitsiades, P. Leif Bergsagel, Esteban Braggio, Lawrence H. Boise, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 249.

https://doi.org/10.1182/blood-2024-204071

Published: 2024

Journal Articles

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 247.

https://doi.org/10.1182/blood-2024-201288

Published: 2024

Journal Articles

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Marios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, Holly Lee, John McIntyre, Marietta Truger, Michael Durante, Bachisio Ziccheddu, Ola Landgren, Leo Rasche, Nizar J. Bahlis, Paola Neri, Francesco Maura

Blood (2024) 144 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2024-212294

Published: 2024

Journal Articles

Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy

Blood (2024) 144 (Supplement 1): 1607.

https://doi.org/10.1182/blood-2024-200927

Published: 2024

Journal Articles

Intrinsic Tumor Drivers and Immune Escape Mechanisms in CD19 CAR T-Cell Therapy Resistance for Aggressive Large B Cell Lymphoma

Bachisio Ziccheddu, Michael D. Jain, Monika Chojnacka, Michael Durante, Venu Venkatarame Gowda Saralamma, Austin Daniel Newsam, Jerald Noble, Nicholas B Figura, Meghan Menges, Ola Landgren, Marco Davila, Jonathan H. Schatz, Francesco Maura, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 232.

https://doi.org/10.1182/blood-2024-208372

Published: 2024

Journal Articles

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 592.

https://doi.org/10.1182/blood-2024-201056

Published: 2024

Journal Articles

Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma

Marios Papadimitriou, Marilena Tauro, Afsaneh Panahi, Bachisio Ziccheddu, Alexandra Maria Poos, Abdessamad Youssfi Alaoui, Dario Magaletti, Mark B. Meads, Kylee H Maclachlan, Marc S. Raab, Gareth Morgan, Saad Z. Usmani, Niels Weinhold, Ola Landgren, Kenneth H. Shain, Florian Kuchenbauer, Francesco Maura

Blood (2024) 144 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2024-211173

Published: 2024

Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Blood (2024) 144 (7): 771–783.

https://doi.org/10.1182/blood.2024024299

Published: 2024

Includes: Supplemental data

Journal Articles

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Marios Papadimitriou, Marilena Tauro, Bachisio Ziccheddu, Alexandra Maria Poos, Abdessamad Youssfi Alaoui, Mark B Meads, Kylee H Maclachlan, Saad Z Usmani, Marc S. Raab, Gareth J. Morgan, Niels Weinhold, Kenneth H. Shain, Ola Landgren, Francesco Maura

Blood (2023) 142 (Supplement 1): 639.

https://doi.org/10.1182/blood-2023-184784

Published: 2023

Journal Articles

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 874.

https://doi.org/10.1182/blood-2023-186802

Published: 2023

Journal Articles

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2023-187891

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomics define neoplastic transformation in multiple myeloma precursor conditions

CAR-T efficacy in large B-cell lymphoma is shaped by neoantigen-driven epitope spreading and limited by HLA loss and genomic instability

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies

Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy

Intrinsic Tumor Drivers and Immune Escape Mechanisms in CD19 CAR T-Cell Therapy Resistance for Aggressive Large B Cell Lymphoma

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only